HNMVX
Price
$32.06
Change
+$0.15 (+0.47%)
Updated
Jun 2 closing price
Net Assets
434.41M
MVCAX
Price
$32.73
Change
+$0.34 (+1.05%)
Updated
Jun 2 closing price
Net Assets
16.77B
Interact to see
Advertisement

HNMVX vs MVCAX

Header iconHNMVX vs MVCAX Comparison
Open Charts HNMVX vs MVCAXBanner chart's image
HNMVX vs MVCAX Comparison Chart in %
View a ticker or compare two or three
VS
HNMVX vs. MVCAX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HNMVX is a StrongBuy and MVCAX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
MVCAX has more cash in the bank: 16.8B vs. HNMVX (434M). HNMVX (1.21) and MVCAX (1.16) have matching dividends . HNMVX was incepted earlier than MVCAX: HNMVX (10 years) vs MVCAX (25 years). MVCAX (0.98) is less costly to investors than HNMVX (0.82). MVCAX is a more actively managed with annual turnover of: 24.00 vs. HNMVX (20.00). MVCAX has a lower initial minimum investment than HNMVX: MVCAX (1000) vs HNMVX (1000000). HNMVX annual gain was more profitable for investors over the last year : 27.06 vs. MVCAX (9.57). HNMVX return over 5 years is better than : 29.59 vs. MVCAX (9.01).
HNMVXMVCAXHNMVX / MVCAX
Total Expense Ratio0.770.9779%
Annual Report Gross Expense Ratio0.820.9884%
Fund Existence10 years25 years-
Gain YTD16.1637.715209%
Front LoadN/A6%-
Min. Initial Investment10000001000100,000%
Min. Initial Investment IRAN/AN/A-
Net Assets434M16.8B3%
Annual Yield % from dividends1.211.16104%
Returns for 1 year27.069.57283%
Returns for 3 years48.5321.83222%
Returns for 5 years29.599.01329%
Returns for 10 years81.0676.09107%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CGTX1.340.09
+7.20%
Cognition Therapeutics
VIV13.490.30
+2.27%
Telefonica Brasil SA
CHEF77.680.71
+0.92%
Chefs' Warehouse (The)
BBOT8.24-0.31
-3.63%
BridgeBio Oncology Therapeutics Inc
APVO5.02-0.22
-4.20%
Aptevo Therapeutics Inc